中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2011年
22期
1533-1537
,共5页
肺疾病,慢性阻塞性%肺功能%圣乔治评分%年龄
肺疾病,慢性阻塞性%肺功能%聖喬治評分%年齡
폐질병,만성조새성%폐공능%골교치평분%년령
Pulmonary disease,chronic obstructive%Pulmonary functions%St.George Questionnaire%Age
目的 探讨圣乔治问卷(SGRQ)与慢性阻塞性肺疾病(COPD)患者肺功能的相关关系及其影响因素.方法 对63例稳定期COPD患者进行SGRQ评分及肺功能测定并对结果进行相关性分析,按GOLD分级分为两组,Ⅱ级(中度)32例,Ⅲ和Ⅳ级(重度至极重度)31例,比较组间SGRQ评分差异;按年龄分为＜70岁组(n=31)和≥70岁组(n=32),对组内肺功能和SGRQ评分进行相关性分析;同意参加治疗随访的36例患者随机分为两组,分别吸入沙美特罗/氟替卡松(50 μg/500 μg,2次/d)及沙丁胺醇/异丙托溴胺(120 μg/21 μg,4次/d)治疗,随访3个月,最终完成随访共34例,分析治疗前后数据.结果 按GOLD分级两组间SGRQ总分及各部分评分差异无统计学意义;＜70岁组用力肺活量占预计值百分比(FVC%)、第1秒用力呼气容积占预计值百分比(FEV1%)、呼气峰流量占预计值百分比(FEFMAX%)、慢肺活量占预计值百分比(SVC%)与SGRQ总分及症状、活动部分评分有轻至中度相关性(r=-0.341～-0.534),≥70岁组仅深吸气量占预计值百分比(IC%)与活动部分评分有一定相关关系(r=-0.412);与沙丁胺醇/异丙托溴胺组相比,沙美特罗/氟替卡松组治疗后SGRQ评分较治疗前显著下降(P=0.001).结论 SGRQ评分结果受年龄因素影响.评价患者用药前后疗效时,SGRQ评分具有参考价值.
目的 探討聖喬治問捲(SGRQ)與慢性阻塞性肺疾病(COPD)患者肺功能的相關關繫及其影響因素.方法 對63例穩定期COPD患者進行SGRQ評分及肺功能測定併對結果進行相關性分析,按GOLD分級分為兩組,Ⅱ級(中度)32例,Ⅲ和Ⅳ級(重度至極重度)31例,比較組間SGRQ評分差異;按年齡分為＜70歲組(n=31)和≥70歲組(n=32),對組內肺功能和SGRQ評分進行相關性分析;同意參加治療隨訪的36例患者隨機分為兩組,分彆吸入沙美特囉/氟替卡鬆(50 μg/500 μg,2次/d)及沙丁胺醇/異丙託溴胺(120 μg/21 μg,4次/d)治療,隨訪3箇月,最終完成隨訪共34例,分析治療前後數據.結果 按GOLD分級兩組間SGRQ總分及各部分評分差異無統計學意義;＜70歲組用力肺活量佔預計值百分比(FVC%)、第1秒用力呼氣容積佔預計值百分比(FEV1%)、呼氣峰流量佔預計值百分比(FEFMAX%)、慢肺活量佔預計值百分比(SVC%)與SGRQ總分及癥狀、活動部分評分有輕至中度相關性(r=-0.341～-0.534),≥70歲組僅深吸氣量佔預計值百分比(IC%)與活動部分評分有一定相關關繫(r=-0.412);與沙丁胺醇/異丙託溴胺組相比,沙美特囉/氟替卡鬆組治療後SGRQ評分較治療前顯著下降(P=0.001).結論 SGRQ評分結果受年齡因素影響.評價患者用藥前後療效時,SGRQ評分具有參攷價值.
목적 탐토골교치문권(SGRQ)여만성조새성폐질병(COPD)환자폐공능적상관관계급기영향인소.방법 대63례은정기COPD환자진행SGRQ평분급폐공능측정병대결과진행상관성분석,안GOLD분급분위량조,Ⅱ급(중도)32례,Ⅲ화Ⅳ급(중도지겁중도)31례,비교조간SGRQ평분차이;안년령분위＜70세조(n=31)화≥70세조(n=32),대조내폐공능화SGRQ평분진행상관성분석;동의삼가치료수방적36례환자수궤분위량조,분별흡입사미특라/불체잡송(50 μg/500 μg,2차/d)급사정알순/이병탁추알(120 μg/21 μg,4차/d)치료,수방3개월,최종완성수방공34례,분석치료전후수거.결과 안GOLD분급량조간SGRQ총분급각부분평분차이무통계학의의;＜70세조용력폐활량점예계치백분비(FVC%)、제1초용력호기용적점예계치백분비(FEV1%)、호기봉류량점예계치백분비(FEFMAX%)、만폐활량점예계치백분비(SVC%)여SGRQ총분급증상、활동부분평분유경지중도상관성(r=-0.341～-0.534),≥70세조부심흡기량점예계치백분비(IC%)여활동부분평분유일정상관관계(r=-0.412);여사정알순/이병탁추알조상비,사미특라/불체잡송조치료후SGRQ평분교치료전현저하강(P=0.001).결론 SGRQ평분결과수년령인소영향.평개환자용약전후료효시,SGRQ평분구유삼고개치.
Objective To study the correlation and influencing factors between the St. George respiratory questionnaire (SGRQ) and lung functions in chronic obstructive pulmonary disease (COPD) patients.Methods Sixty-three stable COPD patients received pulmonary function tests and SGRQ. A correlation analysis of the results was performed.They were divided into two groups according to GOLD (global initiative for chronic obstructive lung disease) classification scheme, 32 patients were in stage Ⅱ (moderate) and 31 in stages Ⅲ and Ⅳ(severe & very severe). And the inter-group SGRQ scores were compared. According to age, they were divided into <70 years group(n=31)and ≥ 70 years group (n=32). The correlations between the SGRQ score and pulmonary functions were analyzed in different age groups. Thirty-six patients willing to participate in treatment and a 3-month follow-up were randomly divided into two groups of treatment with either salmeterol/fluticasone (50 μg/500 μg)(n=18) or salbutamol/ipratropium bromide (120 μg/21 μg)(n=18). The post-therapeutic changes of SGRQ score and pulmonary functions were analyzed.Results There were no significant differences in SGRQ total score and all section score between two groups according to GOLD classification scheme. There were mild to moderate correlations in the <70 years group between lung functions including FVC%, FEV1%, FEFMAX%, SVC% and the SGRQ score including total score, symptoms section score and activity section score. The range of correlation coefficients was -0.341 to -0.534. However, the score only had some correlation with IC% in the ≥70 years group. Compared with the salbutamol/ipratropium bromide treatment group, the SGRQ score of the salmeterol/fluticasone treatment group decreased significantly after therapy (P=0.001).ConclusionInfluenced by age, the SGRQ score can be used to evaluate the clinical efficacy of medications in COPD patients.
